Drug Trial Radar · NCT05569759
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 23, 2023
Primary completion
Apr 30, 2025
Study completion Apr 30, 2025
Sponsor
- Lead sponsor
- Kezar Life Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allowed participants to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.
Conditions
- Autoimmune Hepatitis
Interventions
zetomipzomibDrug
Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
placeboDrug
Subcutaneous injection of placebo
zetomipzomib in open-label extensionDrug
Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patients Who Achieved Complete Biochemical ResponseTime frame: Week 12, Week 16, Week 20, and Week 24
- The Safety and Tolerability of ZetomipzomibTime frame: Baseline through end of study visit (DBTP, Week 28 and OLE, Up to Week 24)
- Proportion of Participants Experiencing a Disease Flare Among the Participants Who Achieved a CR During the Double-blind Treatment PeriodTime frame: Start of open-label extension (OLE) period through End of Study (EOS) up to OLE Week 25
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Keck School of Medicine of USC
Los Angeles, California
University of California, Los Angeles
Los Angeles, California
Stanford Medicine
Redwood City, California
California Pacific Medical Center
San Francisco, California
University of California, San Francisco
San Francisco, California
University of Colorado
Aurora, Colorado
Yale University
New Haven, Connecticut
Mayo Clinic Florida
Jacksonville, Florida
University of Miami
Miami, Florida
Northwestern University
Chicago, Illinois
Rush University
Chicago, Illinois
Indiana University
Indianapolis, Indiana
Ochsner Clinic Foundation
New Orleans, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
Washington University School of Medicine
St Louis, Missouri
Northwell Health Center for Liver Disease and Transplantation
Manhasset, New York
New York University Langone Health/Grossman School of Medicine
New York, New York
Duke University Medical Center
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Virginia Commonwealth University
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.